| Literature DB >> 17173117 |
Marianne Carlsson, Maria Arman, Marie Backman, Ursula Flatters, Thomas Hatschek, Elisabeth Hamrin.
Abstract
Complementary and alternative medicine is used by many cancer patients in most parts of the world, and its use is increasing. The aim of the present study was to examine, over 5 years, the perceived quality of life/life satisfaction in two samples of women with breast cancer who were treated with anthroposophic care or conventional medical treatment only. Data from admission, after 1 year and after 5 years are used for the comparisons. On admission to the study the women in anthroposophic care perceived their quality of life to be lower than that of the women in the conventional treatment group, especially for emotional, cognitive and social functioning and overall quality of life. Sixty women who actively chose treatment with anthroposophic medicine and 60 individually matched women treated with conventional medicine participated. Quality of life was measured by the EORTC QLQ-C30 and the Life Satisfaction Questionnaire. Twenty-six women within anthroposophic care and 31 women within conventional medicine survived the 5 years. Effect size (ES) estimation favored the anthroposophic group in seven of the subscales mostly measuring emotional functioning. The ES for four of the subscales favored the conventional treatment group, mostly concerning physical functioning. After 5 years there were improvements in overall quality of life and in emotional and social functioning compared to admission for the women in anthroposophic care. The improvements took place between admission and 1 year, but not further on. Only minor improvements were found in the matching group.Entities:
Year: 2006 PMID: 17173117 PMCID: PMC1697754 DOI: 10.1093/ecam/nel042
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The frequency of women who answered the EORTC QLQ-C30 and the LSQ on different occasions in ABCW and CBCW
| Occasion | ABCW | CBCW | Matched pairs | ||||
|---|---|---|---|---|---|---|---|
| Participants | Deceased† | Dropouts | Participants | Deceased | Dropouts | ||
| Admission | 60 | 60 | 60 | ||||
| After 4 weeks | 53 | 1 | 6 | 58 | 2 | 52 | |
| After 3 months | 51 | 3 | 6 | 55 | 3 | 2 | 48 |
| After 6 months | 48 | 6 | 6 | 53 | 5 | 2 | 44 |
| After 1 year | 41 | 11 | 8 | 47 | 9 | 4 | 36 |
| After 5 years | 21 | 34 | 5‡ | 23 | 29 | 8 | 13 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
†Cumulative frequency.
‡Three of the eight women who were dropouts during the first year died before the 5 year follow-up.
Figure 1Cumulative survival during 5 years for ABCW and CBCW, respectively.
The means, standard deviations, F and P-values (Wilks lambda and Bonferroni correction) for the scales of the EORTC QLQ-C30, functional scales, for admission, after 1 year and after 5 years
| Scale | ABCW ( | CBCW ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Admission | 1 year | 5 years | Admission | 1 year | 5 years | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| PF | 80.00 | 22.8 | 84.26 | 15.7 | 78.10 | 26.8 | 80.87 | 19.5 | 84.33 | 15.9 | 80.00 | 19.1 |
| RF | 59.53 | 34.0 | 71.43 | 29.9 | 66.67 | 32.9 | 76.09 | 25.3 | 73.91 | 29.7 | 65.22 | 38.2 |
| EF | 54.76 | 18.7 | 73.41 | 16.6 | 67.10 | 19.9 | 72.83 | 25.5 | 66.39 | 30.1 | 72.46 | 27.1 |
| CF | 66.67 | 26.4 | 84.13 | 14.4 | 80.16 | 22.1 | 76.09 | 26.5 | 73.23 | 28.7 | 78.26 | 24.3 |
| SF | 61.11 | 28.1 | 83.33 | 21.7 | 78.57 | 28.5 | 80.43 | 21.1 | 73.26 | 29.2 | 80.43 | 30.4 |
| QL | 46.43 | 20.7 | 66.65 | 15.8 | 67.86 | 19.1 | 61.23 | 28.0 | 60.19 | 29.17 | 69.20 | 24.5 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2 = admission versus 1 year; ***1–3 = admission versus 5 years.
The means, standard deviations, F and P-values (Wilks lambda and Bonferroni correction) for the scales of the EORTC QLQ-C30, symptom scales, for admission, after 1 year and after 5 years
| Scale | ABCW ( | CBCW ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Admission | 1 year | 5 years | Admission | 1 year | 5 years | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| FA | 55.56 | 23.6 | 33.86 | 20.0 | 40.74 | 28.8 | 35.27 | 23.4 | 40.10 | 30.7 | 30.43 | 26.0 |
| NV | 13.49 | 20.2 | 7.14 | 16.3 | 1.59 | 5.0 | 6.52 | 17.2 | 9.42 | 20.0 | 3.62 | 7.0 |
| PA | 39.68 | 29.1 | 17.46 | 18.6 | 22.22 | 27.0 | 25.36 | 29.7 | 24.68 | 29.3 | 23.19 | 33.2 |
| DY | 28.57 | 30.3 | 28.57 | 26.4 | 26.90 | 32.7 | 30.43 | 28.3 | 30.43 | 31.6 | 20.13 | 19.3 |
| SL | 41.27 | 27.7 | 26.98 | 27.1 | 38.10 | 32.1 | 28.79 | 36.1 | 31.86 | 31.7 | 30.30 | 35.5 |
| AP | 14.29 | 27.0 | 3.17 | 10.0 | 4.76 | 12.0 | 4.35 | 11.5 | 11.60 | 21.6 | 0.00 | 0.0 |
| CO | 22.22 | 28.5 | 15.87 | 22.7 | 17.46 | 25.0 | 10.14 | 23.4 | 5.80 | 16.4 | 8.70 | 15.0 |
| DI | 7.94 | 14.5 | 1.59 | 7.3 | 11.67 | 19.1 | 5.80 | 16.4 | 10.14 | 21.2 | 10.14 | 25.5 |
| FI | 42.86 | 46.1 | 36.51 | 40.7 | 28.57 | 33.8 | 18.84 | 22.1 | 17.05 | 24.3 | 18.84 | 33.1 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2 = admission versus 1 year; ***1–3 = admission versus 5 years.
The means, standard deviations, F and P-values (Wilks lambda and Bonferroni correction) for the factors of the LSQ for admission, after 1 year and after 5 years
| Scale | ABCW ( | CBCW ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Admission | 1 year | 5 years | Admission | 1 year | 5 years | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| PS | 84.26 | 13.5 | 90.30 | 10.5 | 87.66 | 12.3 | 89.44 | 10.3 | 88.91 | 12.5 | 91.05 | 11.2 |
| SI | 57.82 | 13.9 | 68.38 | 14.0 | 65.76 | 17.4 | 70.08 | 19.5 | 69.05 | 24.5 | 69.88 | 23.1 |
| QDA | 58.70 | 14.8 | 75.32 | 13.8 | 72.98 | 19.8 | 69.03 | 17.7 | 71.22 | 16.1 | 74.71 | 12.4 |
| SES | 63.66 | 16.6 | 73.47 | 17.0 | 72.79 | 15.3 | 74.35 | 12.6 | 70.37 | 17.1 | 77.44 | 16.5 |
| QFA | 73.47 | 16.2 | 73.74 | 13.6 | 75.65 | 13.7 | 76.03 | 16.5 | 71.30 | 17.4 | 76.05 | 17.0 |
| QFR | 77.14 | 10.4 | 74.29 | 12.2 | 78.50 | 10.2 | 78.73 | 13.8 | 77.11 | 11.2 | 70.56 | 21.2 |
| TotQL | 69.17 | 9.1 | 75.92 | 10.0 | 75.56 | 10.2 | 76.26 | 10.9 | 74.47 | 13.1 | 76.46 | 11.4 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2, admission versus 1 year; ***1–3, admission versus 5 years; ****2–3, 1 year versus 5 years.
The effect sizes (ES) after 5 years, means and standard deviations for the comparison of the scales of the EORTC QLQ-C30 and the factors of the LSQ (n = 13 matched pairs)
| ES† | ABCW | CBCW | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Admission | 5 years | Admission | 5 years | ||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| EORTC QLQ-C30 | |||||||||
| Functional | |||||||||
| PF‡ | −0.30 | 81.54 | 22.3 | 76.92 | 33.5 | 80.00 | 20.0 | 83.08 | 19.7 |
| RF§ | 0.47 | 50.00 | 35.4 | 65.38 | 37.6 | 76.92 | 25.9 | 65.38 | 42.7 |
| EF§ | 0.24 | 54.49 | 18.2 | 67.31 | 22.2 | 66.67 | 26.8 | 70.51 | 30.4 |
| CF§ | 0.22 | 64.10 | 24.4 | 79.49 | 24.7 | 74.36 | 28.6 | 79.49 | 21.7 |
| SF | 0.12 | 66.67 | 27.2 | 74.36 | 33.8 | 82.05 | 22.0 | 84.62 | 28.4 |
| QL | 0.18 | 44.87 | 19.4 | 65.38 | 21.7 | 56.41 | 34.0 | 69.23 | 21.3 |
| Symptom | |||||||||
| FA | −0.04 | 58.35 | 20.7 | 42.72 | 33.9 | 38.46 | 26.7 | 29.06 | 28.9 |
| NV§ | −0.23 | 10.26 | 18.7 | 1.28 | 4.6 | 6.41 | 14.5 | 2.56 | 6.3 |
| PA§ | −0.48 | 46.15 | 29.0 | 20.51 | 26.5 | 28.21 | 33.6 | 25.64 | 37.0 |
| DY‡ | 0.27 | 17.94 | 22.0 | 23.00 | 36.9 | 23.08 | 28.5 | 17.77 | 17.1 |
| SL | 0.05 | 41.03 | 24.2 | 43.59 | 34.4 | 35.90 | 34.6 | 35.90 | 39.6 |
| AP‡ | 0.27 | 5.13 | 12.5 | 5.13 | 12.5 | 5.12 | 12.5 | 0.00 | 0.0 |
| CO‡ | 0.22 | 17.95 | 22.0 | 17.95 | 25.9 | 15.38 | 29.2 | 7.69 | 14.6 |
| DI | −0.13 | 12.82 | 16.9 | 13.72 | 21.3 | 10.26 | 21.0 | 15.38 | 32.2 |
| FI | 0.00 | 38.46 | 46.8 | 33.33 | 36.0 | 25.04 | 24.2 | 20.51 | 39.8 |
| LSQ | |||||||||
| PS | 0.01 | 86.97 | 11.9 | 88.38 | 14.1 | 88.22 | 11.2 | 89.50 | 12.2 |
| SI | 0.10 | 57.88 | 11.6 | 64.65 | 19.9 | 68.13 | 20.9 | 72.16 | 24.7 |
| QDA | 0.02 | 60.13 | 14.9 | 71.23 | 21.9 | 67.82 | 20.3 | 76.29 | 12.1 |
| SES§ | 0.28 | 66.02 | 14.1 | 71.98 | 15.7 | 74.45 | 14.2 | 75.55 | 20.1 |
| QFA | 0.16 | 70.33 | 18.2 | 73.36 | 14.9 | 72.09 | 17.9 | 71.47 | 19.1 |
| QFR§ | 0.88 | 75.38 | 11.5 | 78.24 | 10.3 | 74.95 | 14.7 | 64.40 | 24.5 |
| TotQL | 0.15 | 69.45 | 8.5 | 74.35 | 11.6 | 74.28 | 12.1 | 74.90 | 12.9 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
†ES = 0.20–0.50, small; ES = 0.50–0.80, moderate; ES > 0.80, large (22).
‡In favor of the CBCW.
§In favor of the ABCW.
The outcome of the matching procedure concerning prognosis on admission and survival after 5 years
| Prognosis | ABCW ( | CBCW ( | ||
|---|---|---|---|---|
| Favorable | Unfavorable | Favorable | Unfavorable | |
| Still alive | 25 | 1 | 26 | 5 |
| Deceased | 10 | 24 | 9 | 20 |
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.